The FirstTake Podcast – Gilead’s oncology strategy under the spotlight

FirstTake on Pharma - Pharma News and Analysis Podcast

English - March 10, 2022 19:00 - 15 minutes - 11.5 MB - ★★★★★ - 2 ratings
Science pharma pharmaceutical intelligence firstword firsttake cardiovascular dermatology diabetes immunology infectious diseases Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: The FirstTake Podcast – Where next for gene editing?

Next Episode: The FirstTake Podcast – Sanofi’s breast cancer hopeful fails to deliver

On this week’s episode FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss why Gilead is getting flak for a positive cancer drug study, what’s gone wrong at bluebird bio and why the FDA has been so quick to expand approval of Bristol Myers Squibb’s Opdivo for the treatment of neoadjuvant lung cancer.